A recent study found that PET using carbon-11-labeled Pittsburgh Compound B and MRI were able to differentiate Alzheimer's disease patients from those with Lewy body dementia at early stages of the diseases. Validation of the results in a larger study might help determine the right treatment for these patients, the lead author said.

Related Summaries